{"id":166,"date":"2023-09-23T09:49:27","date_gmt":"2023-09-23T09:49:27","guid":{"rendered":"http:\/\/fydemo.com\/ibnsina-wp\/?page_id=166"},"modified":"2026-06-24T09:35:03","modified_gmt":"2026-06-24T09:35:03","slug":"share-corporate-info","status":"publish","type":"page","link":"https:\/\/www.ibnsina-pharma.com\/ar\/share-corporate-info\/","title":{"rendered":"\u062d\u0635\u0635 \u0648 \u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0627\u0644\u0634\u0631\u0643\u0629"},"content":{"rendered":"
\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0639\u0646 \u0627\u0644\u0633\u0647\u0645\u00a0<\/strong><\/h5>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/tr>\n
\u0627\u0644\u0639\u0645\u0644\u0629<\/td>\n\u062c\u0646\u064a\u0647 \u0645\u0635\u0631\u064a (EGP)<\/td>\n<\/tr>\n
\u0627\u0644\u0633\u0648\u0642<\/td>\n\u0627\u0644\u0628\u0648\u0631\u0635\u0629 \u0627\u0644\u0645\u0635\u0631\u064a\u0629 (EGX)<\/td>\n<\/tr>\n
\u0627\u0644\u0642\u0637\u0627\u0639<\/td>\n\u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u0635\u062d\u064a\u0629 \u0648\u0627\u0644\u0623\u062f\u0648\u064a\u0629<\/td>\n<\/tr>\n
\u0631\u0645\u0632 \u0627\u0644\u0634\u0631\u0643\u0629<\/td>\nISPH.CA<\/td>\n<\/tr>\n
\u0643\u0648\u062f \u0627\u0644\u062a\u0631\u0642\u064a\u0645 \u0627\u0644\u062f\u0648\u0644\u064a<\/td>\nEGS512O1C012<\/td>\n<\/tr>\n
\u062a\u0627\u0631\u064a\u062e \u0627\u0644\u0625\u062f\u0631\u0627\u062c<\/td>\n8 \/ 11 \/ 2017<\/td>\n<\/tr>\n
\u0639\u062f\u062f \u0627\u0644\u0623\u0633\u0647\u0645 \u0627\u0644\u0645\u062f\u0631\u062c\u0629<\/td>\n1,008,000,000<\/td>\n<\/tr>\n
\u0627\u0644\u0642\u064a\u0645\u0629 \u0627\u0644\u0625\u0633\u0645\u064a\u0629 \/ \u0627\u0644\u0633\u0647\u0645<\/td>\n0.25 \u062c\u0646\u064a\u0647 \u0645\u0635\u0631\u064a (\u062e\u0645\u0633\u0629 \u0648 \u0639\u0634\u0631\u0648\u0646 \u0642\u0631\u0634\u0627)<\/td>\n<\/tr>\n
\u0631\u0623\u0633 \u0627\u0644\u0645\u0627\u0644 \u0627\u0644\u0645\u0635\u0631\u062d \u0628\u0647<\/td>\n1,000,000,000 \u062c\u0646\u064a\u0647 \u0645\u0635\u0631\u064a (\u0645\u0644\u064a\u0627\u0631 \u062c\u0646\u064a\u0647 \u0645\u0635\u0631\u064a)<\/td>\n<\/tr>\n
\u0631\u0623\u0633 \u0627\u0644\u0645\u0627\u0644 \u0627\u0644\u0645\u0635\u062f\u0631<\/td>\n252,000,000 EGP (two hundred and fifty two million Egyptian Pounds)<\/td>\n<\/tr>\n
\u0631\u0623\u0633 \u0627\u0644\u0645\u0627\u0644 \u0627\u0644\u0645\u062f\u0641\u0648\u0639<\/td>\n252,000,000 EGP (two hundred and fifty two million Egyptian Pounds)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

\u0647\u064a\u0643\u0644 \u0627\u0644\u0645\u0633\u0627\u0647\u0645\u064a\u0646<\/strong><\/h5>\n
Ibnsina Pharma\u2019s shareholders include prominent members of the Egyptian business community and large institutional shareholders that have allowed the company to significantly enhance its corporate governance practices and systems. The company\u2019s shareholders include the Mahgoub family (10.1%), the Abdel Gawad family (15.6%), Faisal Islamic Bank (14.0%), and C3 Capital Consortium (4.5%)<\/h5>\n
\"\"<\/h5>\n
\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0639\u0646 \u0627\u0644\u0634\u0631\u0643\u0629<\/strong><\/h5>\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/tr>\n
\u0633\u0646\u0629 \u0627\u0644\u062a\u0623\u0633\u064a\u0633<\/td>\n2001<\/td>\n<\/tr>\n
\u0631\u0642\u0645 \u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u062a\u062c\u0627\u0631\u064a<\/td>\n\u0633\u062c\u0644 \u062a\u062c\u0627\u0631\u064a \u0631\u0642\u0645 10724 \u0628\u062a\u0627\u0631\u064a\u062e 28\/8\/2017 \u0645\u0643\u062a\u0628 \u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u062a\u062c\u0627\u0631\u064a \u0628\u0627\u0644\u0642\u0627\u0647\u0631\u0629.<\/td>\n<\/tr>\n
\u0627\u0644\u0633\u0646\u0629 \u0627\u0644\u0645\u0627\u0644\u064a\u0629<\/td>\n1 \u064a\u0646\u0627\u064a\u0631 \u2013 31 \u062f\u064a\u0633\u0645\u0628\u0631.<\/td>\n<\/tr>\n
\u0642\u0627\u0646\u0648\u0646 \u0627\u0644\u062d\u0643\u0645<\/td>\n\u0642\u0627\u0646\u0648\u0646 (159) \u0644\u0633\u0646\u0629 1981.<\/td>\n<\/tr>\n
\u0627\u0644\u063a\u0631\u0636 \u0645\u0646 \u0627\u0644\u0634\u0631\u0643\u0629<\/td>\n\u0627\u0628\u0646 \u0633\u064a\u0646\u0627 \u200b\u200b\u0641\u0627\u0631\u0645\u0627 \u0647\u064a \u0634\u0631\u0643\u0629 \u0639\u0627\u0645\u0629 \u0645\u062f\u0631\u062c\u0629 \u0641\u064a \u0627\u0644\u0628\u0648\u0631\u0635\u0629 \u0627\u0644\u0645\u0635\u0631\u064a\u0629 \u0645\u0646\u0630 \u062f\u064a\u0633\u0645\u0628\u0631 2017. \u062a\u0639\u0645\u0644 \u0627\u0628\u0646 \u0633\u064a\u0646\u0627 \u200b\u200b\u0641\u0627\u0631\u0645\u0627 \u0641\u064a \u0642\u0637\u0627\u0639 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0648 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0648 \u0639\u0644\u0648\u0645 \u0627\u0644\u062d\u064a\u0627\u0629 \u0645\u0639 \u0627\u0644\u062a\u0631\u0643\u064a\u0632 \u0639\u0644\u0649 \u0627\u0644\u0623\u062f\u0648\u064a\u0629. \u064a\u0642\u0639 \u0645\u0642\u0631 \u0627\u0628\u0646 \u0633\u064a\u0646\u0627 \u200b\u200b\u0641\u0627\u0631\u0645\u0627 \u0641\u064a \u0627\u0644\u0642\u0627\u0647\u0631\u0629\u060c \u0645\u0635\u0631<\/td>\n<\/tr>\n
\u0625\u0633\u0645 \u0627\u0644\u0645\u0631\u0627\u062c\u0639<\/td>\n\u062e\u0627\u0644\u062f \u0627\u0644\u063a\u0627\u0646\u0645 \u0648 \u0639\u064a\u0633\u0649 \u0627\u0644\u0631\u0641\u0627\u0639\u064a \u0648 \u0634\u0631\u0643\u0627\u0626\u0647\u0645.<\/td>\n<\/tr>\n
\u0645\u0642\u0631<\/td>\n\u0645\u062f\u064a\u0646\u0629 \u0627\u0644\u0639\u0628\u0648\u0631\u060c \u0627\u0644\u0645\u0646\u0637\u0642\u0629 \u0627\u0644\u0635\u0646\u0627\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649\u060c \u0628\u0644\u0648\u0643 12015\u060c \u0645\u0635\u0631<\/td>\n<\/tr>\n
\u0627\u0644\u0634\u0631\u0643\u0627\u062a \u0627\u0644\u062a\u0627\u0628\u0639\u0629 \u0644\u0646\u0627<\/td>\n– AIM for Investment and Consulting in Healthcare
\n– Ramp Logistics
\n– DIGI 360
\n– Ibnsina Trade<\/td>\n<\/tr>\n
\u0645\u062c\u0644\u0633 \u0627\u0644\u0625\u062f\u0627\u0631\u0629<\/td>\n\u0639\u0628\u062f \u0627\u0644\u0639\u0632\u064a\u0632 \u0639\u0644\u064a
\n\u0645\u062d\u0633\u0646 \u0645\u062d\u062c\u0648\u0628
\n\u0631\u0623\u0641\u062a \u0645\u0642\u0628\u0644 \u062d\u0633\u064a\u0646
\n\u0645\u062d\u0645\u0648\u062f \u0639\u0628\u062f \u0627\u0644\u062c\u0648\u0627\u062f
\n\u0639\u0645\u0631 \u0639\u0628\u062f \u0627\u0644\u062c\u0648\u0627\u062f
\n\u0623\u062d\u0645\u062f \u0639\u0628\u062f \u0627\u0644\u062c\u0648\u0627\u062f
\n\u0645\u062d\u0645\u062f \u0645\u062d\u062c\u0648\u0628
\n\u0645\u062d\u0645\u062f \u0632\u0643\u064a
\n– Sahar Nasr
\n\u0647\u062f\u0649 \u0648\u0627\u0644\u064a<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/h3>\n

 <\/p>\n

\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0627\u0644\u0625\u062f\u0631\u0627\u062c \u0641\u064a \u0627\u0644\u0628\u0648\u0631\u0635\u0629\u00a0<\/strong><\/h5>\n

\u0627\u0644\u0627\u0643\u062a\u062a\u0627\u0628 \u0627\u0644\u0639\u0627\u0645 \u0648 \u0627\u0644\u0627\u0643\u062a\u062a\u0627\u0628 \u0627\u0644\u0639\u0627\u0645 \u0641\u064a \u0627\u0644\u0633\u0648\u0642 \u0627\u0644\u062b\u0627\u0646\u0648\u064a\u0629<\/p>\n

\n

Ibnsina Pharma S.A.E. intends to proceed with an initial public offering on the Egyptian Exchange (the “Offering”) that is expected to consist of a primary Offering of newly issued shares and a secondary Offering of existing shares held by the Company\u2019s current shareholders (collectively the \u201cShares\u201d) constituting up to 38% of Ibnsina Pharma\u2019s total shares. Proceeds from the transaction will be used to grow Ibnsina\u2019s core distribution business and support its expansion into new, higher-margin revenue streams. The Offering is expected to take place in late Q4 2017 or early Q1 2018, subject to market conditions and the receipt of regulatory approvals.<\/p>\n

Start of Trading Announcement (PDF)<\/a><\/p>\n

Retail Offering Conclusion Announcement (PDF)<\/a><\/p>\n

Final Price Announcement (PDF)<\/a><\/p>\n

Price Range Announcement (PDF)<\/a><\/p>\n

EGX Listing Announcement (PDF)<\/a><\/p>\n

Intention to Float (PDF)<\/a><\/p>\n<\/div>\n

<\/h5>\n

 <\/p>\n

\n
\u0627\u0644\u0645\u0639\u0627\u0645\u0644\u0627\u062a \u0627\u0644\u062f\u0627\u062e\u0644\u064a\u0629\u00a0<\/strong><\/h5>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u0627\u0644\u0645\u062a\u062f\u0627\u0648\u0644<\/strong><\/td>\n\u0627\u0644\u0646\u0648\u0639<\/strong><\/td>\n\u0627\u0644\u0643\u0645\u064a\u0629<\/strong><\/td>\n\u0627\u062e\u0631 \u062a\u062d\u062f\u064a\u062b<\/strong><\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n70,000<\/td>\n20 May 2026<\/td>\n<\/tr>\n
Insider<\/td>\nBuy<\/td>\n10,000<\/td>\n06 May 2026<\/td>\n<\/tr>\n
Insider<\/td>\nBuy<\/td>\n10,000<\/td>\n30 April 2026<\/td>\n<\/tr>\n
Insider<\/td>\nBuy<\/td>\n20,000<\/td>\n07 April 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n400,000<\/td>\n02 April 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n50,000<\/td>\n02 April 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n300,000<\/td>\n02 April 2026<\/td>\n<\/tr>\n
Insider<\/td>\nBuy<\/td>\n18,360<\/td>\n17 March 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n1,100,336<\/td>\n12 March 2026<\/td>\n<\/tr>\n
Insider<\/td>\nBuy<\/td>\n10,600<\/td>\n10 March 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n50,000<\/td>\n18 February 2026<\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n35,000<\/td>\n08 February 2026<\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n32,000<\/td>\n08 February 2026<\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n85,000<\/td>\n05 February 2026<\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n500,000<\/td>\n05 February 2026<\/td>\n<\/tr>\n
Insider<\/td>\nSell<\/td>\n30,000<\/td>\n28 January 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n221,219<\/td>\n15 January 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n400,000<\/td>\n14 January 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n236,626<\/td>\n13 January 2026<\/td>\n<\/tr>\n
Related Parties for Insider<\/td>\nSell<\/td>\n342,155<\/td>\n12 January 2026<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n24 November 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n400,000<\/td>\n02 November 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n02 November 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n50,000<\/td>\n27 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n885,000<\/td>\n23 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,300<\/td>\n20 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n28,100<\/td>\n15 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n13,510<\/td>\n14 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n08 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n2,729,809<\/td>\n07 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n3,404,809<\/td>\n07 October 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n200,000<\/td>\n21 September 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n452,896<\/td>\n18 September 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n15,000<\/td>\n16 September 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n2,672,045<\/td>\n15 September 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n8,940<\/td>\n27 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n26 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n50,000<\/td>\n25 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,430<\/td>\n21 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n36,950<\/td>\n20 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n31,000<\/td>\n18 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n25,000<\/td>\n17 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,000<\/td>\n17 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n04 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,000<\/td>\n03 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n03 August 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n31,400<\/td>\n22 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n20,000<\/td>\n21 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n16 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n27,000<\/td>\n10 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n07 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n44,020<\/td>\n07 July 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,500<\/td>\n24 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n3,500<\/td>\n24 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n23 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n150,000<\/td>\n16 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,290<\/td>\n15 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n9,000<\/td>\n11 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n12,000<\/td>\n10 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n01 June 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n75,000<\/td>\n18 May 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,400<\/td>\n04 May 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n04 May 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,000<\/td>\n23 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n8,000<\/td>\n22 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n15,000<\/td>\n17 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n16 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n15,000<\/td>\n15 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n12,730<\/td>\n14 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n156,825<\/td>\n13 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n90,000<\/td>\n10 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n2,200<\/td>\n09 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n08 April 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n6,700<\/td>\n06 January 2025<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n491,000<\/td>\n31 December 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n20,000<\/td>\n17 December 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n12 December 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n10 December 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n71,053<\/td>\n01 December 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n72,156<\/td>\n26 November 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n18 November 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n14 October 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n748,005<\/td>\n10 October 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n20,500<\/td>\n08 October 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n200,000<\/td>\n07 October 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n530,666<\/td>\n21 May 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n497,199<\/td>\n02 April 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,500,000<\/td>\n25 March 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,000,000<\/td>\n24 March 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n2,150,000<\/td>\n20 March 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n2,661,332<\/td>\n19 March 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n2,000,000<\/td>\n06 March 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,000,000<\/td>\n21 February 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,200,000<\/td>\n20 February 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n600,000<\/td>\n04 February 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n400,000<\/td>\n01 February 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,000,000<\/td>\n31 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n23 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n235,000<\/td>\n14 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n665,000<\/td>\n11 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n04 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n02 January 2024<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n50,000<\/td>\n24 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n200,000<\/td>\n21 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n19 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n200,000<\/td>\n18 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n17 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,000,000<\/td>\n14 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n600,000<\/td>\n13 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n12 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n11 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n10 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n100,000<\/td>\n07 December 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n300,000<\/td>\n30 November 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n200,000<\/td>\n20 November 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n500,000<\/td>\n19 November 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n75,000<\/td>\n19 June 2023<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n878,983<\/td>\n15 December 2022<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n700,000<\/td>\n14 December 2022<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,500,000<\/td>\n12 January 2022<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,013,134<\/td>\n29 November 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,013,134<\/td>\n29 November 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n24,315,216<\/td>\n29 July 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n24,315,216<\/td>\n29 July 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n25,000<\/td>\n07 June 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n100,000<\/td>\n02 June 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n935,000<\/td>\n11 February 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n950,000<\/td>\n26 January 2021<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n80,000<\/td>\n17 December 2020<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n70,000<\/td>\n16 December 2020<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n7,600<\/td>\n14 January 2020<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n3,000<\/td>\n05 January 2020<\/td>\n<\/tr>\n
European Bank for Reconstruction and Development<\/td>\nSell<\/td>\n11,419,999<\/td>\n05 September 2019<\/td>\n<\/tr>\n
Mohamed Mohsen Mohamed Mahgoub<\/td>\nSell<\/td>\n7,500,000<\/td>\n05 September 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n230,000<\/td>\n20 August 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n194,219<\/td>\n14 August 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,600,000<\/td>\n08 August 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n250,000<\/td>\n03 June 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n5,200<\/td>\n08 April 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,858<\/td>\n04 April 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n745<\/td>\n03 April 2019<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n3,300<\/td>\n31 December 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n2,200<\/td>\n30 December 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,771<\/td>\n25 December 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n1,137<\/td>\n04 December 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,000<\/td>\n18 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n23,100<\/td>\n17 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n3,125<\/td>\n10 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n950<\/td>\n09 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,100<\/td>\n08 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n3,000<\/td>\n04 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,000<\/td>\n01 October 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nSell<\/td>\n341,378<\/td>\n28 June 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n82,390<\/td>\n19 February 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n10,000<\/td>\n18 February 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n20,000<\/td>\n06 February 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n23,480<\/td>\n05 February 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n13,712<\/td>\n04 February 2018<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n50,000<\/td>\n25 December 2017<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n8,100<\/td>\n21 December 2017<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n1,530<\/td>\n17 December 2017<\/td>\n<\/tr>\n
Undisclosed<\/td>\nBuy<\/td>\n6,760<\/td>\n14 December 2017<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>","protected":false},"excerpt":{"rendered":"

Share Information\u00a0 Currency Egyptian Pound (EGP) Market Egyptian Stock Exchange (EGX) Sector Health Care & Pharmaceuticals Ticker ISPH.CA ISIN Code EGS512O1C012 Date of Listing 8 \/ 11 \/ 2017 Number of Listed Shares 1,008,000,000 Par Value \/ Share 0.25 EGP (twenty five piasters) Authorized Capital 1,000,000,000 EGP (one billion Egyptian Pounds) Issued Capital 252,000,000 EGP […]<\/p>\n","protected":false},"author":1,"featured_media":959,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"investors-details-page.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-166","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/pages\/166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/comments?post=166"}],"version-history":[{"count":37,"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/pages\/166\/revisions"}],"predecessor-version":[{"id":1250,"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/pages\/166\/revisions\/1250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/media\/959"}],"wp:attachment":[{"href":"https:\/\/www.ibnsina-pharma.com\/ar\/wp-json\/wp\/v2\/media?parent=166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}